Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

Stock Information for Sierra Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sierra Oncology Inc.

Codexis Announces CEO Transition Effective August 9, 2022
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
Sierra Oncology Reports First Quarter 2022 Results
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates BKI, SAIL, SRRA, ATRS
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CMPI, SBOW, SRRA, ATRS

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.